SMMT

Summit Therapeutics Inc

Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.

HC Wainwright reduced their price target on Summit Therapeutics from $30.00 to $23.00 and set a "buy" rating for the company in a report on Monday...

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by...

Wall Street Zen upgraded shares of Summit Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday...

Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - What's Next...

Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first quarter financial results. Here's what you should know.read more...

Futures Rise, Oil Slides On Iran Ceasefire Optimism After Best Month For Stocks Since 2020 US equity futures are higher, set for a new all time high, as the rally that's pushed Wall Street to record...

Pictet Asset Management Holding SA decreased its holdings in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 13.7% during the 4th quarter, according to its most recent disclosure with the SEC...